Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis - 05/12/20
, Anne-Sofie Halling, MD a, b, Alexander Egeberg, MD, PhD a, b, Lone Skov, MD, DMSc a, bAbstract |
Background |
Multiple biologics for psoriasis exist, and interleukin (IL) 17 inhibitors are among those with the best efficacy. However, switching treatment is often required at some point, and intraclass switch of IL-17 inhibitors is not well investigated.
Objectives |
To determine the efficacy of a second IL-17 inhibitor in patients with psoriasis.
Methods |
Two authors independently searched the databases PubMed and EMBASE for studies reporting on efficacy of IL-17 inhibitors in patients with psoriasis previously exposed to another IL-17 inhibitor. The study was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Results |
In total, 14 publications comprising 655 patients were included. The proportion of patients achieving a reduction of 75%, 90%, and 100% in Psoriasis Area Severity Index were, respectively, 74.6 (95% confidence interval [CI], 63.9-84.0), 69.4% (95% CI, 53.2-83.4), and 46.4 (95% CI, 30.5-62.7) after short-term treatment (weeks 9, 12, and 16 combined).
Limitations |
Most studies included were on ixekizumab and were retrospective chart reviews with no information on the response to the previous IL-17 inhibitor.
Conclusion |
Previous treatment with an IL-17 inhibitor does not appear to affect the efficacy of another IL-17 inhibitor in the treatment of psoriasis. However, further prospective studies are needed.
Le texte complet de cet article est disponible en PDF.Key words : biologics, IL-17, intraclass switch
Abbreviations used : IL, PASI75, PASI90, PASI100, PGA, Th
Plan
| Funding sources: None. |
|
| Disclosure: Dr Loft has been an honorary speaker for Eli Lilly and Janssen Cilag. Dr Egeberg has received research funding from Pfizer, Eli Lilly, Novartis, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation and honoraria as a consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Samsung Bioepis Co, Ltd, Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol Myers Squibb, and Janssen Pharmaceuticals. Dr Skov has been a paid speaker for AbbVie, Eli Lilly, Novartis, and LEO Pharma; has been a consultant or has served on advisory boards with AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, UCB, Almirall, and Sanofi; has served as an investigator for AbbVie, Sanofi, Janssen Cilag, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Novartis, Regeneron, and LEO Pharma; and has received research and educational grants from Novartis, Sanofi, Janssen-Cilag, and LEO Pharma. Dr Halling has no conflicts of interest to declare. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
Vol 84 - N° 1
P. 130-138 - janvier 2021 Retour au numéro
Article précédent
- Proceeding report of the Fourth Symposium on Hidradenitis Suppurativa Advances 2019
- Shanthi Narla, Kyla N. Price, Muskaan Sachdeva, Monica Shah, Vivian Shi, Iltefat Hamzavi, Afsaneh Alavi, Michelle A. Lowes
- Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis
- Anne-Sofie Halling, Nikolai Loft, Jonathan I. Silverberg, Emma Guttman-Yassky, Jacob P. Thyssen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?